Biomedical Engineering Reference
In-Depth Information
Rodriguez D (1998) Decisions of pharmaceutical firms for new product development. MIT
Industrial Performance Working Paper.
http://web.mit.edu/ipc/publications/pdf/Decisions.pdf
.
Ross SA, Westerfield RW, Jordan BD (2003) Fundamentals of corporate finance. McGraw-Hill,
New York
Ruefli TW, Collins JM, Lacugna JR (1999) Risk measures in strategic management research: auld
lang syne? Strateg Manag J 20(2):167-194
Santhanam R, Kyparisis GJ (1996) A decision model for interdependent information system
project selection. Eur J Oper Res 89(2):380-399
Senn S (2007) Statistical issues in drug development. Wiley, Chichester, West Sussex
Sharpe WF (1964) Capital asset prices: a theory of market equilibrium under conditions of risk.
J Finance 19(3):425-442
Shenhar AJ, Dvir D (2007) Reinventing project management: the diamond approach to successful
growth and innovation. Boston: Harvard Business Press
Simester D, Zhang J (2010) Why are bad products so hard to kill? Manag Sci 56(7):1161-1179
Singh JV (1986) Performance, slack, and risk taking in organizational decision making. Acad
Manag J 29(3):562-585
Smith J (1999) Much ado about options. Decision Analysis Newsletter 1999
Sorescu AB, Chandy RK, Prabhu JC (2003) Sources and financial consequences of radical innova-
tion: insights from pharmaceuticals. J Mark 67(4):82-102
Sorescu AB, Chandy RK, Prabhu JC (2007) Why some acquisitions do better than others: product
capital as a driver of long-term stock returns. J Mark Res 44(1):57-72
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML (2011) The role of
public-sector research in the discovery of drugs and vaccines. N Engl J Med 364(6):535-541
Stremersch S, Van Dyck W (2009) Marketing of the life sciences: a new framework and research
agenda for a nascent field. J Mark 73(4):4-30
Szydlowski M (2012) Incentives, project choice and dynamic multitasking. Working Paper
Taggart JH, Blaxter TH (1992) Strategy in pharmaceutical R&D: a portfolio risk matrix. R&D
Management 22(3):241-254
Talias MA (2007) Optimal decision indices for R&D project evaluation in the pharmaceutical
industry: Pearson index versus Gittins index. Eur J Oper Res 177(2):1105-1112
Tan B, Anderson EG, Dyer JS Jr, Parker GG (2010) Evaluating system dynamics models of risky
projects using decision trees: alternative energy projects as an illustrative example. Syst Dynam
Rev 26(1):1-17
Taylor N (2009) Pfizer unveils post-Wyeth takeover R&D structure.
http://www.in-
Accessed Sept 2011
Tellis GJ, Prabhu JC, Chandy RK (2009) Radical innovation across nations: the preeminence of
corporate culture. J Mark 73(1):3-23
Vincent LH, Bharadwaj SG, Challagalla GN (2004) Does innovation mediate firm performance?:
a meta-analysis of determinants and consequences of organizational innovation. Working
Paper
Weber R, Werners B, Zimmermann HJ (1990) Planning models for research and development. Eur
J Oper Res 48(2):175-188
Weingartner HM (1966) Capital budgeting of interrelated projects: survey and synthesis. Manag
Sci 12(7):485-516
Wernerfelt B (1985) The capital asset pricing model and strategic planning. Manag Sci 31(4):510
Wuyts S, Dutta S, Stremersch S (2004) Portfolios of interfirm agreements in technology-intensive
markets: consequences for innovation and profitability. J Mark 68(2):88-100
Yeoh P-L (1994) Speed to global markets: an empirical prediction of new product success in the
ethical pharmaceutical industry. Eur J Mark 28(11):29-49
Ziemkiewicz C, Kosara R (2010) Beyond bertin: seeing the forest despite the trees. IEEE Comput
Graph Appl 30(5):7-11
Search WWH ::
Custom Search